Potential anti-inflammatory effects of 5-lipoxygenase inhibition - Exemplified by the leukotriene synthesis inhibitor BAY X 1005

被引:0
作者
Muller-Peddinghaus, R [1 ]
机构
[1] Bayer AG, Business Grp Pharma, Inst Cardiovasc & Arteriosclerosis Res, D-42096 Wuppertal, Germany
来源
JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY | 1997年 / 48卷 / 04期
关键词
inflammation; leukotriene; 5-lipoxygenase; leukotriene synthesis inhibitor; BAY X 1005; allergic asthma;
D O I
暂无
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Leukotrienes have been identified in various pathophysiologies. The leukotrienes LTB4 and LTC4 are assigned to inflammation. 5-lipoxygenase inhibitors which inhibit the synthesis of LTA(4) being the precursor of both LTB4 and LTC4 appear to have only a limited antiinflammatory potential. 5-lipoxygenase inhibitors are represented by direct and indirect inhibitors, the latter competing with substrate transfer from the five-lipoxygenase activating protein (FLAP) to the 5-lipoxygenase enzyme. 5-lipoxygenase Inhibition under experimental condition results in inhibition of edema formation, neutrophil infiltration, smooth muscle contraction after antigen challenge and prevention of early and late allergic reactions. Only in the cysteinyl-leukotriene-driven pathophysiology of allergic asthma and allergic rhinitis 5-lipoxygenase inhibition appears to provide symptomatic relief. Yet, the overall-antiinfiammatory effect in man is far less than expected, but may be outweighed by the nearly total lack of any side effects of 5-lipoxygenase inhibition pei se.
引用
收藏
页码:529 / 536
页数:8
相关论文
共 27 条
[1]  
ALLEN SP, 1993, CARDIOSCIENCE, V4, P47
[2]   Antiedematous effects of combination therapies with the leukotriene synthesis inhibitor BAY X 1005 in the archidonic acid-induced mouse ear inflammation test [J].
Burchardt, ER ;
MullerPeddinghaus, R .
PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, 1997, 56 (04) :301-306
[3]  
DEJONG EMGJ, 1991, SKIN PHARMACOL, V4, P278
[4]   REQUIREMENT OF A 5-LIPOXYGENASE-ACTIVATING PROTEIN FOR LEUKOTRIENE SYNTHESIS [J].
DIXON, RAF ;
DIEHL, RE ;
OPAS, E ;
RANDS, E ;
VICKERS, PJ ;
EVANS, JF ;
GILLARD, JW ;
MILLER, DK .
NATURE, 1990, 343 (6255) :282-284
[5]   IN-VITRO PHARMACOLOGY OF BAY-X1005, A NEW INHIBITOR OF LEUKOTRIENE SYNTHESIS [J].
FRUCHTMANN, R ;
MOHRS, KH ;
HATZELMANN, A ;
RADDATZ, S ;
FUGMANN, B ;
JUNGE, B ;
HORSTMANN, H ;
MULLERPEDDINGHAUS, R .
AGENTS AND ACTIONS, 1993, 38 (3-4) :188-195
[6]   INHIBITION OF ANTIGEN-INDUCED CONTRACTION OF GUINEA-PIG AIRWAYS BY A LEUKOTRIENE SYNTHESIS INHIBITOR, BAY X1005 [J].
GARDINER, PJ ;
CUTHBERT, NJ ;
FRANCIS, HP ;
FITZGERALD, MF ;
THOMPSON, AM ;
CARPENTER, TG ;
PATEL, UP ;
NEWTON, BB ;
MOHRS, K ;
MULLERPEDDINGHAUS, R ;
TAYLOR, WA .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1994, 258 (1-2) :95-102
[7]  
GORENNE I, 1994, J PHARMACOL EXP THER, V268, P868
[8]   SLOW-REACTING SUBSTANCES (LEUKOTRIENES) CONTRACT HUMAN AIRWAY AND PULMONARY VASCULAR SMOOTH-MUSCLE INVITRO [J].
HANNA, CJ ;
BACH, MK ;
PARE, PD ;
SCHELLENBERG, RR .
NATURE, 1981, 290 (5804) :343-344
[9]  
Hatzelmann A, 1994, Adv Prostaglandin Thromboxane Leukot Res, V22, P23
[10]   MODE OF ACTION OF THE NEW SELECTIVE LEUKOTRIENE SYNTHESIS INHIBITOR BAY X-1005 ((R)-2-[4-(QUINOLIN-2-YL-METHOXY)PHENYL]-2-CYCLOPENTYL ACETIC-ACID) AND STRUCTURALLY RELATED-COMPOUNDS [J].
HATZELMANN, A ;
FRUCHTMANN, R ;
MOHRS, KH ;
RADDATZ, S ;
MULLERPEDDINGHAUS, R .
BIOCHEMICAL PHARMACOLOGY, 1993, 45 (01) :101-111